Sandoz Canada announces launch of lisdexamfetamine

Sandoz Canada announced the launch of Sandoz Lisdexamfetamine, a generic equivalent of Vyvanse, approved for the same indications. It follows the recent launches of Sandoz Amoxicillin, Sandoz Desvenlafaxine and Sandoz Riociguat. Sandoz Lisdexamfetamine is available on the Canadian market in bottles of 100 capsules of 10 mg to 70 mg that can be taken whole or opened and mixed with yogurt, water or orange juice. Their appearance is similar to the original product to facilitate patients’ transition. Lisdexamfetamine is indicated for Attention Deficit Hyperactivity Disorder in children six years of age or older, adolescents and adults, as well as for moderate to severe Binge Eating Disorder in adults. Studies have shown that untreated ADHD can have negative impacts on self-esteem and social function1 as well as on academic performance. This launch should enable Sandoz to continue to help improve patients’ quality of life, at a more affordable price.